二甲双胍联合格列美脲治疗非酒精性脂肪肝合并2型糖尿病肥胖患者的效果观察

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect ofmetformin combined with glimepiride in the treatment of non-alcoholic fatty liver disease（NAFLD）companied with obese type 2 diabetes patients（T2DM）.M ethods 62 patientswith NAFLD with obese T2DM in our hospital from April 2014 to June 2015 were selected and randomly divided into group A（30 cases）and group B（32 cases）.On the basis of the treatment ofmetformin，group A was given glimepiride，group B was treated with pioglitazone.The change of liver function，blood glucose，blood lipid，bodymass index（BMI），insulin resistance　（HOMA-IR）and adverse reaction was compared between the two groups before and after treatment.Results The level of ALT，AST，TC，TG，LDL-C、BMI，FPG，2 h PG，HbA1c，HOMA-IR after treatment in the two groups was lower than that before treatment，the level of FINS，HOMA-βF after treatment in the two groupswas higher than that before treatment，with significant difference　（P＜0.05）.There was no significant difference in the HDL-C level between the two groups before and after treatment（P＞0.05）.The level of HbA1c，2 h PG and BMIafter treatment in group A was lower than that in group B after treatment，with significant difference　（P＜0.05）.There was no serious adverse reaction in each groups.Conclusion The results suggest both therapies could effectively improve glucose and lipid metabolism，reduce enzyme and insulin resistance in NAFLD with obese T2DM patients with metformin combined with glimepiride or pioglitazone，butmetformin combined with glimepiride can improve glucosemore better and can be used to as an effective treatment for patientswith NAFLD combined with T2MD.

Key words： Metformin Glimepiride Obesity Type 2 diabetesmellitus Non-alcoholic fatty liver disease

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Lei
	KE Rui-qiong
	OUYANG Can-hui
	LIAO Yue-guang
	HUANGCai-bin

Cite this article:

ZHANG Lei,KE Rui-qiong,　OUYANG Can-hui, et al. Effect observation of metform in combined w ith glimepiride in the treatment of obese patient w ith type 2 diabetesmellitus com panied w ith nonalcoholic fatty liver disease[J]. 中国当代医药, 2016, 23(20): 132-134.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I20/132

［1］	中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪肝病诊疗指南［J］.中华肝脏病杂志，2006，14（3）：161-163.
［5］	黄婷婷，周玉荣，张向君，等.非酒精性脂肪肝治疗进展［J］.医学综述，2015，21（8）：1406-1409.
［6］	张四青，钟树妹，郭经琴.非酒精性脂肪肝患者的胰岛素抵抗和胰岛β细胞功能的临床研究［J］.井冈山大学学报（自然科学版），2010，31（5）：125-128.
［8］	唐纪兰，文新年，韦凌云.吡格列酮对非酒精性脂肪性肝病患者胰岛素抵抗及内皮功能的影响［J］.中华实用诊断与治疗杂志，2015，29（3）：303-305.
［9］	任玉莲，张志敏.二甲双胍联合盐酸小檗碱治疗非酒精性脂肪肝的疗效观察［J］.现代中西医结合杂志，2015，24（6）：633-635.
［10］	陈丹丹.吡格列酮及二甲双胍对非酒精性脂肪性肝病合并糖尿病疗效分析［J］.实用糖尿病杂志，2015，11（6）：38-39.
［2］	张荣，陈侃，夏玉敬，等.二甲双胍治疗非酒精性脂肪性肝病合并糖尿病的研究进展［J］.世界临床药物，2016，37（3）：214-216.
［3］	Wong VW.Nonalcoholic fatty liver disease in Asia：a story of growth［J］.JGastroenterol Hepatol，2013，28（1）：18-23.
［4］	曾静波，庄晓明，穆君.二甲双胍联合吡格列酮对初发2型糖尿病并发非酒精性脂肪肝的疗效及对血清Vaspin水平的影响［J］.河北医科大学学报，2015，36（5）：509-512.
［7］	Doycheva I，Loomba R.Effect ofmetformin on ballooningdegeneration in nonalcoholic steatohepatitis（NASH）：when to usemetformin in nonalcoholic fatty liver disease（NAFLD）［J］. Adv Ther，2014，31（1）：30-43.
［11］	张四青，习燕华，钟树妹，等.格列美脲联合二甲双胍对新诊断2型糖尿病伴非酒精性脂肪肝病患者胰岛素抵抗和胰岛β细胞功能的影响［J］.中国全科医学，2016，19 （5）：525-528.
［12］	中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病的诊疗指南（2011年修订版）［J］.中华肝脏病杂志，2010，18（3）：163-166.
［13］	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2010年版）［M］.北京：北京大学医学出版社，2011：15-22.
［14］	洪世华，吴菊琴，柯瑞琼，等.甘精胰岛素联合格列美脲对比联合吡格列酮治疗初诊2型糖尿病疗效观察［J］.中国糖尿病杂志，2014，22（12）：1113-1115.
［15］	许小平，郑晓华.格列美脲联合胰岛素治疗2型糖尿病的疗效及对胰岛素剂量的影响［J］.中国老年学杂志，2013，33（6）：1417-1418.